BrainsWay Ltd.
HealthcareNASDAQ:BWAY · NASDAQ Global Market
-$0.06 today
Vol 0.04M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.4%
avg -28.1%
ROIC
4.7%
avg -16.2%
ROA
6.8%
avg -13.9%
Analysis
ROE is currently the strongest return metric at 10.4% versus its period average of -28.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Hadar Levy | Chief Executive Officer | $542,495.00 | — | 52 | $123,050.00 | 0.31% |
Michael Cohen | Vice President of US Sales | $397,438.00 | — | — | — | — |
Colleen Hanlon | Vice President of Medical Affairs | $327,488.00 | — | 46 | $53,881.00 | 0.14% |
Ido Marom | Chief Financial Officer | $303,199.00 | — | 50 | $51,250.00 | 0.13% |
Yiftach Roth | Founder & Chief Scientific Officer | $108,000.00 | — | 55 | $1.08M | 2.75% |
Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | $69,921.00 | — | 56 | $905,963.00 | 2.31% |
Avner Hagai | Founder & Director | $41,989.00 | — | 70 | $6,250.00 | 0.02% |
David Zacut | Co-Founder & Vice-Chairman | $40,246.00 | — | 73 | $0.00 | <0.01% |
Dor Hagai | Vice President of Operations | — | — | — | — | — |
Menachem C. Klein | Vice President, General Counsel & Corporate Secretary | — | — | — | — | — |
Gilead Moiseyev | Chief Technology Officer | — | — | 54 | $52,500.00 | 0.13% |
Naomi Rozenfeld | Chief Marketing Officer | — | — | — | $25,000.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$0.00
Net Sentiment
+$0.00
Net buying
Most Active
Mitrany Rayten Michal Ety
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| May 26, 2026 | Mitrany Rayten Michal Ety Direct | Sell | 8.0K | $0.00 | $0.00 | |
| May 25, 2026 | Mitrany Rayten Michal Ety Direct | Sell | 10.0K | $0.00 | $0.00 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $0.00 over the last 12 months. That adds up to net buying of $0.00. Mitrany Rayten Michal Ety was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +113.2% | +20.6% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +113.2% over three years. Forward estimates point to Revenue at +20.6% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tactile Systems Technology, Inc.
NASDAQ:TCMD
$593.46M
NeuroPace, Inc.
NASDAQ:NPCE
$533.23M
Cerus Corporation
NASDAQ:CERS
$512.94M
Delcath Systems, Inc.
NASDAQ:DCTH
$404.59M
Viemed Healthcare, Inc.
NASDAQ:VMD
$400.62M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
RxSight, Inc.
NASDAQ:RXST
$194.98M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
Who manages BWAY?
BrainsWay Ltd. (BWAY) lists 12 active executives. The top listed executive is Dor Hagai, Vice President of Operations.
Are BWAY insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.